Angela Hwang is the Group President of the Pfizer Biopharmaceuticals Group and a member of the company’s Executive Leadership Team.
In this role, she leads all Pfizer’s innovative medicines businesses; a global organization that operates in more than 125 countries, with a portfolio of more than 600 products generating approximately three-quarters of Pfizer’s revenues. It encompasses six global businesses: Oncology, Inflammation & Immunology, Rare Disease, Vaccines, Internal Medicine, and Hospital; and an Emerging Markets group. Each of these areas supports a robust innovative pipeline, and partners with Pfizer’s research and clinical development teams to bring breakthrough medicines to market.
Previously, Angela was the Group President of Pfizer Essential Health. Pfizer Essential Health was a leader in non-viral Anti-Infectives, Biosimilars, off-patent Sterile Injectables, and the Emerging Markets. Its Global Brands portfolio included many of Pfizer’s most iconic brands, including Lipitor, Viagra, and Norvasc.
Angela joined Pfizer in 1997 and has held more than 10 different positions in the company spanning strategy, product development, marketing, sales, and general management. Her experience covers a wide array of therapeutic areas and medicines in all stages of their lifecycle, as well as geographical breadth in both developed and emerging markets.
Angela currently sits on the board of the European Federation of Pharmaceutical Industries and Associations (EFPIA) and has been an active participant in industry groups such as BIO, where she co-chaired the Vaccines Policy Committee for two years. Angela is also a Board member for the Pfizer Foundation, a charitable organization working to expand healthcare access for people around the world and the Executive Sponsor for Pfizer’s Global Asian Alliance, a network that provides professional networking, leadership training, mentoring and opportunities to celebrate the ethnic and cultural diversity of Pfizer’s Asian community. A native of South Africa, Angela received her Bachelor of Science in Microbiology and Biochemistry from the University of Cape Town and her MBA from Cornell University.